At the beginning of 2009, Dianne Wysowski of the US Food and Drug Administration summarized 23 reports of esophageal1 cancer following alendronate use. Wysowski also noted that there had been 31 cases following alendronate use in Europe and Japan and ten cases in which other bisphosphonates had been reported as concomitant or suspect treatment.